Methotrexate drug holiday improves vaccine efficacy in RA | ACR


  • Conference reports - RSi Communications
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with rheumatoid arthritis (RA) who stop taking methotrexate treatment for just 2 wks after they have a seasonal influenza shot can improve the vaccine’s efficacy without increasing RA disease activity. 

Why this matters

  • Methotrexate can lower vaccine efficacy in people with RA. 

Study design

  • Seoul National University Hospital researchers conducted a prospective, multicenter, randomized, parallel-group trial in October 2016 to January 2017.
  • 316 patients with RA taking a stable methotrexate dose were randomly assigned to two groups: 156 continued regular methotrexate and 160 discontinued their dose for 2 wks after receiving their shot.
  • All participants were vaccinated with a seasonal, quadrivalent influenza vaccine containing H1N1, H3N2, B-Yamagata, and B-Victoria.
  • Primary outcome was frequency of satisfactory response to the vaccine, which was defined as the patients having a fourfold or greater increase in hemaglutination inhibition (HI) antibody titer at 4 wk after vaccination against two or more vaccine strains. 

Key results

  • 75.5% of patients who temporarily discontinued methotrexate achieved a satisfactory vaccine response compared to 54.5% of patients who continued regular dosing.
  • After vaccination, the seroprotection rate was higher for all four antigens measured in the group who held off methotrexate for two wks than those who continued.